The tablet boxes, produced by Novartis AG, sit at a pharmacy counter.
Bloomberg | Bloomberg | Getty images
The Swiss Pharmaceutical firm Novartis said Thursday that he expects his Kisqali breast cancer treatment to be the next medication of great success within his portfolio, since he seeks to move away the confidence of his heart failure therapy.
Kisqali sales, which deals with metastatic breast cancer, increased 64% worldwide in a constant currency in the three months until June, the company said in its second quarter sales report. Which includes a 100% growth in the US.
It follows a 56% increase in Kisqali sales in the first quarter to March.
Speaking in a gain call, CEO Vas Narasimhan said that Kisqali was the drug with the greatest reach for higher performance.
It is projected that the diagnoses and deaths of global breast cancer will increase by 2050, according to the Cancer Agency of the World Health Organization, with 1 out of 20 women around the world who are diagnosed with breast cancer in their lives.
That could be translated into 3.2 million new cases and 1.1 million deaths a year worldwide by 2050 if current trends continue, the study found, significantly exceeding 2.3 million new cases of 2022 and 670,000 related deaths.
Narasimhan also cited the “strong pipe” of Novartis of other medications, including its pluvicto prostate cancer treatment and its stoward for chronic myeloid leukemia, which it was also “on the way to be a box office success.”
“We continue to generate strong performance in our ongoing releases for Kisqali, Pluvicto and Scemplix, demonstrating the replacement power in our portfolio,” he added in a statement that accompanies the results.
The comments occur when Novartis seeks to shake his dependence on his drug of heart failure of the best selling entrese, which faces the expiration of the US patent. UU. Next year. Interest brought $ 7.8 billion in 2024, representing about 15% of the company's general global sales.
Thursday said that it expects generic drug manufacturers to begin to produce imitating versions of the drug in mid -2025, although that timeline is “subject to current IP [intellectual property] and regulatory litigation. “
On Wednesday, a federal judge from the United States rejected Novartis's request for a preliminary court order to prevent MSN Pharmaceuticals from selling a generic version of the medication before the patent expires.
Entrest sales increased 22% in the second quarter, in line with the previous three months.
“In the short term, it is an important product for us,” said outgoing financial director Harry Kirsch about between Thursday.
“We have IP that we are defending. If we succeed in further defending our appeal, every month we will have a significant and pleasant advantage,” he added.
In general, the net sales of the second novartis quarter increased 11% in a constant currency base to $ 14.05 billion, just $ 14.18 billion estimated by analysts in a LSEG survey.
Meanwhile, the central operating income adjusted quarterly rose 21% to $ 5.93 billion, slightly above the $ 5.69 billion expected.
Novartis said that now he hopes that the central operating income of the whole year will grow in “low adolescents”, above “low double digit” previously, while retaining his prognosis for the growth of sales in the digits of a single high digit.
The company also announced a repurchase of shares of up to $ 10 billion, citing “trust” in its growth in the middle and long term.
